Superluminal Medicines raises $60M Series B for AI driven obesity drugs

Superluminal sits at the intersection of two powerful trends: the reshaping of drug discovery around structure-based AI models and the gold rush into metabolic disease. Its pitch is that combining protein dynamics, structural biology and proprietary machine learning can systematically unlock difficult GPCR targets, not just throw models at random screening. The fact that specialist biotech investors like BVF and Perceptive are leaning in, alongside Nvidia’s venture arm and Lilly, signals that the market believes this stack is maturing from hype into repeatable pipelines.

For the AGI conversation, this is not about building a general reasoning system, but it is about using increasingly capable models as engines inside scientific workflows. The more capital that flows into platforms like this, the more high quality, experimentally grounded data will be generated to train future models that reason about biology. That feedback loop between wet lab and AI is exactly the kind of domain-specific superintelligence many people expect long before anything like a general human-level system.

It also underlines how concentrated AI value capture may be in verticals where incumbents like Lilly can plug model-first startups into global clinical and commercial machines. If this model works for GPCRs in obesity, expect similar structures to proliferate across oncology, immunology and CNS, each powered by slightly different AI architectures tuned to their targets.